<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">3 Biotech</journal-id><journal-id journal-id-type="iso-abbrev">3 Biotech</journal-id><journal-title-group><journal-title>3 Biotech</journal-title></journal-title-group><issn pub-type="ppub">2190-572X</issn><issn pub-type="epub">2190-5738</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28330110</article-id><article-id pub-id-type="pmc">4729761</article-id><article-id pub-id-type="publisher-id">352</article-id><article-id pub-id-type="doi">10.1007/s13205-015-0352-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Singh</surname><given-names>Krishna P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Verma</surname><given-names>Neeraj</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Akhoon</surname><given-names>Bashir A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bhatt</surname><given-names>Vishal</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Shishir K.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Shailendra K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Smita</surname><given-names>Suchi</given-names></name><address><phone>+491523191592</phone><email>suchi.smita@med.uni-rostock.de</email><email>suchismi@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Department of Bioinformatics, CSIR-Indian Institute of Toxicology Research, Lucknow, 226001 India </aff><aff id="Aff2"><label>2</label>Society for Biological Research and Rural Development, Kanpur, 208014 India </aff><aff id="Aff3"><label>3</label>Department of Bioinformatics, Biocenter, University of W&#x000fc;rzburg, Am Hubland, 97074 W&#x000fc;rzburg, Germany </aff><aff id="Aff4"><label>4</label>Department of Systems Biology and Bioinformatics, University of Rostock, 18057 Rostock, Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2016</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>39</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Human papilloma virus (HPV) is the primary etiological agent responsible for cervical cancer in women. Although in total 16 high-risk HPV strains have been identified so far. Currently available commercial vaccines are designed by targeting mainly HPV16 and HPV18 viral strains as these are the most common strains associated with cervical cancer. Because of the high level of antigenic specificity of HPV capsid antigens, the currently available vaccines are not suitable to provide cross-protection from all other high-risk HPV strains. Due to increasing reports of cervical cancer cases from other HPV high-risk strains other than HPV16 and 18, it is crucial to design vaccine that generate reasonable CD8+ T-cell responses for possibly all the high-risk strains. With this aim, we have developed a computational workflow to identify conserved cross-clade CD8+ T-cell HPV vaccine candidates by considering E1, E2, E6 and E7 proteins from all the high-risk HPV strains. We have identified a set of 14 immunogenic conserved peptide fragments that are supposed to provide protection against infection from any of the high-risk HPV strains across globe.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s13205-015-0352-z) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HPV</kwd><kwd>Epitope</kwd><kwd>Cytotoxic</kwd><kwd>T lymphocytes</kwd><kwd>Cervical cancer</kwd><kwd>Vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; King Abdulaziz City for Science and Technology 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Cervical cancer is the second most common malignant cancer in terms of incidence and mortality rates in women worldwide after breast cancer (Pisani et al. <xref ref-type="bibr" rid="CR40">1993</xref>; Collins et al. <xref ref-type="bibr" rid="CR12">2006</xref>; Jemal et al. <xref ref-type="bibr" rid="CR28">2011</xref>; Senapathy et al. <xref ref-type="bibr" rid="CR47">2011</xref>; Torre et al. <xref ref-type="bibr" rid="CR54">2015</xref>). Human papilloma virus (HPV) is considered as the major etiological agent for cervical cancer which is responsible for over 265,700 total women deaths per year with around 527,600 new cases every year (Torre et al. <xref ref-type="bibr" rid="CR54">2015</xref>). It is estimated that about 80&#x000a0;% of women could acquire a HPV infection in their lifetime (Baseman and Koutsky <xref ref-type="bibr" rid="CR6">2005</xref>). On an average, every woman who dies due to cervical cancer loses about 26&#x000a0;years of life which is considerably greater than the average years of life lost to breast cancer (19.2&#x000a0;years) (Herzog and Wright <xref ref-type="bibr" rid="CR26">2007</xref>; Pandhi and Sonthalia <xref ref-type="bibr" rid="CR37">2011</xref>). Till now over 200 types of HPV strains have been sequenced (Bernard et al. <xref ref-type="bibr" rid="CR7">2010</xref>; Meiring et al. <xref ref-type="bibr" rid="CR34">2012</xref>; McLaughlin-Drubin <xref ref-type="bibr" rid="CR32">2015</xref>; Supindham et al. <xref ref-type="bibr" rid="CR53">2015</xref>), among them 16 are known to be high-risk virus strains (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 73, and 82) (Mu&#x000f1;oz et al. <xref ref-type="bibr" rid="CR35">2003</xref>; Markowitz et al. <xref ref-type="bibr" rid="CR31">2007</xref>; Sumalee et al. <xref ref-type="bibr" rid="CR52">2008</xref>; Meijer et al. <xref ref-type="bibr" rid="CR33">2009</xref>; Dames et al. <xref ref-type="bibr" rid="CR13">2014</xref>) with oncogenic HPV DNAs detected in 99&#x000a0;% of the cervical cancers (Dunne et al. <xref ref-type="bibr" rid="CR15">2007</xref>). High-risk HPV strains are in most of the cases identified as main etiological agents in cervical, anal, and other genital cancers, among them about 70&#x000a0;% of cervical cancers worldwide are only due to HPV strains 16 and 18 (Dunne et al. <xref ref-type="bibr" rid="CR15">2007</xref>). For the primary prevention of cervical cancer, HPV vaccines are widely used as an important added tool (Ault et al. <xref ref-type="bibr" rid="CR4">2004</xref>; Fife et al. <xref ref-type="bibr" rid="CR18">2004</xref>; Liu et al. <xref ref-type="bibr" rid="CR30">2012</xref>). Prophylactic and the therapeutic formulation are the two strategies for cervical cancer vaccine candidates. Recently, FDA approved a vaccine named &#x02018;Gardasil 9&#x02019; that protects females between the ages of 9&#x02013;26 against nine HPV strains. More specifically, the first generation of Gardasil vaccine was capable to provide protections against four HPV strains (HPV-6, HPV-11, HPV-16, and HPV-18) while the latest approved version of Gardasil vaccine (Gardasil 9) provides protection against five additional high-risk HPV strains (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58) responsible for almost 20&#x000a0;% of cervical cancers worldwide (Braaten and Laufer <xref ref-type="bibr" rid="CR9">2008</xref>; Petrosky et al. <xref ref-type="bibr" rid="CR38">2015</xref>). Gardasil and Cervarix are prophylactic vaccines and offer no therapeutic benefit for persons already infected with HPV (Wain <xref ref-type="bibr" rid="CR57">2010</xref>; Pandhi and Sonthalia <xref ref-type="bibr" rid="CR37">2011</xref>). Most of the vaccine candidates that can be used as therapeutic vaccines include immunogenic fragments from early proteins (targets for cellular immunity) for the resolution of precancerous lesions and cervical cancer (Huh and Roden <xref ref-type="bibr" rid="CR27">2008</xref>). The protection offered by current vaccines is primarily against HPV types (16 and 18), although cross-protection for other high-risk HPV strains cannot be neglected. The identification of highly conserved cross-clade epitopes suitable for therapeutic intervention is clearly a crucial prerequisite for epitope-based vaccines development and for diagnostic tests to distinguish infection from high or low risk HPV strains. Cytotoxic T-cell (CTL) cross-reactivity is alleged to play an essential role in generating immune responses (Frankild et al. <xref ref-type="bibr" rid="CR19">2008</xref>; Petrova et al. <xref ref-type="bibr" rid="CR39">2012</xref>). HPV-specific cytotoxic CD8+ T lymphocytes immune responses can be detected in all untreated cervical cancer patients (Eiben et al. <xref ref-type="bibr" rid="CR16">2002</xref>; Valdespino et al. <xref ref-type="bibr" rid="CR56">2005</xref>). In animal models, cell-mediated immunity is considered to be an important mechanism for abolition of subclinical or neoplasic virus-infected cells, particularly CTL which lyses tumor cells in an antigen-specific manner (Chen et al. <xref ref-type="bibr" rid="CR11">1991</xref>; Feltkamp et al. <xref ref-type="bibr" rid="CR17">1993</xref>; De Bruijn et al. <xref ref-type="bibr" rid="CR14">1998</xref>; Torres-Poveda et al. <xref ref-type="bibr" rid="CR55">2014</xref>). Instead of individual epitopes, the use of the full-length protein with a great amount of immunogenic peptides may have a better chance to induce specific CTLs, as shown previously (Strobel et al. <xref ref-type="bibr" rid="CR51">2000</xref>; Adams et al. <xref ref-type="bibr" rid="CR1">2003</xref>; Bet et al. <xref ref-type="bibr" rid="CR8">2015</xref>) but the protection from all high-risk HPV strains from single vaccination will still be a question. Selection of immunogenic consensus conserved epitopes from the proteins of all HPV high-risk strains may provide an experimental basis for designing of universal HPV T-cell vaccines. In the present work, we identified conserved consensus immunogenic CD8+ T-cell epitopes from the proteome of all high-risk HPV strains and proposed a peptide pool with the ability to show immunogenic responses against all the known high-risk HPV strains.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Sequence retrieval</title><p>Complete proteome of all the 16 high-risk HPV strains was retrieved from UniProt Knowledgebase (Apweiler et al. <xref ref-type="bibr" rid="CR3">2004</xref>). Amino acid sequences of four HPV proteins E1, E2, E6 and E7 were extracted from all the selected proteomes. Subsequently, four sequence datasets were manually prepared for each of the proteins from 16 high-risk HPV strains.</p></sec><sec id="Sec4"><title>Conservancy analysis</title><p>For conservancy analysis, sequence datasets were first individually aligned using ClustalW software. The substitution model was set to BLOSUM, since the mentioned substitution matrix is based on amino acid pairs in blocks of aligned protein segments, hence performs better in alignments and homology searches compared to those based on accepted mutations in closely related groups (Henikoff and Henikoff <xref ref-type="bibr" rid="CR25">1992</xref>). Conservancy of the amino acids of HPV strains among the aligned sequences of datasets was estimated by Shannon entropy function using protein variability server (PVS). Shannon entropy analysis (Shannon <xref ref-type="bibr" rid="CR48">1948</xref>) is one of the most sensitive tools to estimate the diversity of a system. For a multiple protein sequence alignment, the Shannon entropy (<italic>H</italic>) for every position is calculated as follows<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$H = - \mathop \sum \limits_{i = 1}^{M} {\text{P}}_{\text{i}} { \log }_{2} {\text{P}}_{\text{i}}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi>H</mml:mi><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:munderover><mml:mo movablelimits="false">&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:msub><mml:mtext>P</mml:mtext><mml:mtext>i</mml:mtext></mml:msub><mml:msub><mml:mo>log</mml:mo><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mtext>P</mml:mtext><mml:mtext>i</mml:mtext></mml:msub></mml:mrow></mml:math><graphic xlink:href="13205_2015_352_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>where Pi is the fraction of residues of amino acid type <italic>i</italic> and <italic>M</italic> is the number of amino acid types.</p><p>Consequently, consensus sequences were created for individual conserved fragments within Shannon entropy threshold 2 from corresponding aligned sequence datasets&#x000a0;(Gupta et al. <xref ref-type="bibr" rid="CR23">2012</xref>). The consensus sequences were further used for the identification of MHC binders.</p></sec><sec id="Sec5"><title>Prediction of MHC binders</title><p>The most selective step in the presentation of antigenic peptides to T-cell receptor (TCR) is the binding of the peptide to the MHC molecule (Yewdell and Bennink <xref ref-type="bibr" rid="CR58">1999</xref>). NetMHC 3.2 server was used to predict binding of peptides to a number of different HLA alleles using artificial neural networks (ANNs) and weight matrices. Position specific scoring matrices (PSSMs)-based SYFPEITHI (Rammensee et al. <xref ref-type="bibr" rid="CR41">1999</xref>) method was employed for the prediction of binding peptides of major histocompatibility complex (MHC) class I. NetMHC 3.2 predicts epitopes with length ranging from 8 to 11 amino acids. Only epitopes with IC50 value below 500&#x000a0;nM were considered as the potential epitopes in ANNs-based prediction from the consensus fragments for four protein datasets. As the epitopes were predicted from the consensus sequences of conserved protein fragments, these epitopes were again realigned with E1, E2, E6 and E7 proteins of all high-risk HPV strains. Only those epitopes were kept for subsequent analyses which were 100&#x000a0;% identical to their respective proteins. Further, we performed common allele matrix analysis (Gupta et al. <xref ref-type="bibr" rid="CR21">2010</xref>) to discard those epitopes whose allelic response is coverd by more efficient epitopes from the same high-risk HPV strain.</p></sec><sec id="Sec6"><title>Prediction of non-human homologous immunogenic peptide fragments</title><p>All the overlapping epitopes (9&#x000a0;mer) were merged to design the potential immunogenic peptide fragments for CD8+ response from each of the protein datasets. A number of immunogenic peptides may fail to raise a T-cell response if they are recognized as self peptides due to significant similarity exists between the antigenic peptides and proteins of host organism. For this, the final sets of potential immunogenic peptide fragments were checked for their similarities with annotated human proteins using offline BLAST similarity search.</p></sec><sec id="Sec7"><title>Population coverage analysis</title><p>Population coverage analysis plays a significant role in the epitope-based vaccine designing because of the highly polymorphic nature of the MHC molecules (Reche and Reinherz <xref ref-type="bibr" rid="CR44">2003</xref>; Stern and Wiley <xref ref-type="bibr" rid="CR50">1994</xref>). Population coverage of newly identified immunogenic peptide fragments were individually analyzed using population coverage tool available at IEDB web server. The tool calculates the response of individuals set of peptide fragments with known MHC- I restrictions on the basis of maximum HLA binding alleles. The average projected population coverage of class I epitopes for the populations distributed in various human populations (ethnicities) was estimated.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><p>The E1, E2, E6 and E7 protein sequences from all high-risk HPV strains were collected from UniProtKB and aligned using multiple sequence alignment software clustalW. The multiple alignment files for all the four protein data sets with conserved regions are shown in Supplementary File 1. The conserved fragments within aligned strains of sequence datasets were analyzed by PVS with variability threshold (<italic>H</italic>)&#x000a0;&#x02264;&#x000a0;2.0. Typically, positions with <italic>H</italic>&#x000a0;&#x02265;&#x000a0;2.0 are considered variable, whereas those with <italic>H</italic>&#x000a0;&#x02264;&#x000a0;1 are consider highly conserved (Litwin and Jores <xref ref-type="bibr" rid="CR29">1992</xref>). Additionally the positions with <italic>H</italic>&#x000a0;&#x02264;&#x000a0;2 and <italic>H</italic>&#x000a0;&#x0003e;&#x000a0;1 are also considered as conserved regions (Gupta et al. <xref ref-type="bibr" rid="CR20">2009</xref>, <xref ref-type="bibr" rid="CR22">2011</xref>). The default cutoff value (<italic>H</italic>&#x000a0;=&#x000a0;1) was too strict, resulting in fewer and smaller targets for the following analysis so the cutoff threshold value was set as 2.0 in the present analysis to identify reasonable conserved fragments with length &#x02265;9 amino acid residues. The consensus sequences of all the conserved regions with length &#x02265;9 amino acids in four datasets of E1, E2, E6 and E7 proteins from high-risk HPV strains are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Conserved protein fragments from E1, E2, E6 and E7 protein datasets from all high-risk HPV strains</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">HPV protein</th><th align="left">Conserved fragment number</th><th align="left">Start position</th><th align="left">End position</th><th align="left">Sequence with nine or more consecutive conserved residues filtered from protein variability server</th></tr></thead><tbody><tr><td align="left" rowspan="22">E1</td><td align="left">E1-1</td><td char="." align="char">2</td><td char="." align="char">12</td><td align="left">MADPEGTDGEG</td></tr><tr><td align="left">E1-2</td><td char="." align="char">21</td><td char="." align="char">31</td><td align="left">VEAIVEKKTGD</td></tr><tr><td align="left">E1-3</td><td char="." align="char">33</td><td char="." align="char">41</td><td align="left">ISDDEDENA</td></tr><tr><td align="left">E1-4</td><td char="." align="char">66</td><td char="." align="char">76</td><td align="left">ETAQALFNAQE</td></tr><tr><td align="left">E1-5</td><td char="." align="char">135</td><td char="." align="char">146</td><td align="left">PDSGYGNTEVET</td></tr><tr><td align="left">E1-6</td><td char="." align="char">241</td><td char="." align="char">257</td><td align="left">ELVRPFKSDKTTCTDWV</td></tr><tr><td align="left">E1-7</td><td char="." align="char">265</td><td char="." align="char">278</td><td align="left">PSVAEGLKTLIKPY</td></tr><tr><td align="left">E1-8</td><td char="." align="char">291</td><td char="." align="char">307</td><td align="left">WGVIILMLIRFKCGKNR</td></tr><tr><td align="left">E1-9</td><td char="." align="char">312</td><td char="." align="char">321</td><td align="left">KLLSTLLNVP</td></tr><tr><td align="left">E1-10</td><td char="." align="char">324</td><td char="." align="char">334</td><td align="left">CMLIEPPKLRS</td></tr><tr><td align="left">E1-11</td><td char="." align="char">336</td><td char="." align="char">352</td><td align="left">AAALYWYRTGISNISEV</td></tr><tr><td align="left">E1-12</td><td char="." align="char">362</td><td char="." align="char">373</td><td align="left">RQTVLQHSFDDS</td></tr><tr><td align="left">E1-13</td><td char="." align="char">375</td><td char="." align="char">388</td><td align="left">FDLSEMVQWAFDND</td></tr><tr><td align="left">E1-14</td><td char="." align="char">406</td><td char="." align="char">447</td><td align="left">NSNAAAFLKSNCQAKYVKDCATMCRHYKRAQKRQMSMSQWIK</td></tr><tr><td align="left">E1-15</td><td char="." align="char">455</td><td char="." align="char">474</td><td align="left">DGGDWRPIVQFLRYQGVEFI</td></tr><tr><td align="left">E1-16</td><td char="." align="char">483</td><td char="." align="char">516</td><td align="left">FLKGTPKKNCIVIYGPANTGKSYFGMSLIHFLQG</td></tr><tr><td align="left">E1-17</td><td char="." align="char">535</td><td char="." align="char">545</td><td align="left">DAKIAMLDDAT</td></tr><tr><td align="left">E1-18</td><td char="." align="char">555</td><td char="." align="char">572</td><td align="left">YMRNALDGNPISIDRKHR</td></tr><tr><td align="left">E1-19</td><td char="." align="char">574</td><td char="." align="char">590</td><td align="left">LVQLKCPPLLITSNINP</td></tr><tr><td align="left">E1-20</td><td char="." align="char">595</td><td char="." align="char">606</td><td align="left">RWPYLHSRLTVF</td></tr><tr><td align="left">E1-21</td><td char="." align="char">624</td><td char="." align="char">642</td><td align="left">INDKNWKSFFSRTWSRLDL</td></tr><tr><td align="left">E1-22</td><td char="." align="char">645</td><td char="." align="char">653</td><td align="left">EEEDKENDG</td></tr><tr><td align="left" rowspan="6">E2</td><td align="left">E2-1</td><td char="." align="char">7</td><td char="." align="char">26</td><td align="left">METLSQRLNVCQDKILDHYE</td></tr><tr><td align="left">E2-2</td><td char="." align="char">45</td><td char="." align="char">54</td><td align="left">ECAIFYKARE</td></tr><tr><td align="left">E2-3</td><td char="." align="char">77</td><td char="." align="char">89</td><td align="left">QAIELQMALESLN</td></tr><tr><td align="left">E2-4</td><td char="." align="char">110</td><td char="." align="char">118</td><td align="left">TEPKKCFKK</td></tr><tr><td align="left">E2-5</td><td char="." align="char">204</td><td char="." align="char">212</td><td align="left">CPESVSSTS</td></tr><tr><td align="left">E2-6</td><td char="." align="char">305</td><td char="." align="char">314</td><td align="left">TTPIVHLKGD</td></tr><tr><td align="left" rowspan="5">E6</td><td align="left">E6-1</td><td char="." align="char">14</td><td char="." align="char">23</td><td align="left">ERPRKLHDLC</td></tr><tr><td align="left">E6-2</td><td char="." align="char">25</td><td char="." align="char">33</td><td align="left">ALETSLHDI</td></tr><tr><td align="left">E6-3</td><td char="." align="char">76</td><td char="." align="char">86</td><td align="left">FYSKISEYRHY</td></tr><tr><td align="left">E6-4</td><td char="." align="char">113</td><td char="." align="char">127</td><td align="left">CQKPLCPEEKQRHLD</td></tr><tr><td align="left">E6-5</td><td char="." align="char">129</td><td char="." align="char">137</td><td align="left">KKRFHNIAG</td></tr><tr><td align="left" rowspan="2">E7</td><td align="left">E7-1</td><td char="." align="char">6</td><td char="." align="char">15</td><td align="left">PTLQDIVLDL</td></tr><tr><td align="left">E7-2</td><td char="." align="char">95</td><td char="." align="char">103</td><td align="left">LQQLLMGTL</td></tr></tbody></table></table-wrap>
</p><p>To generate immunological responses against any pathogen, the binding of antigenic peptide from pathogen and its binding affinity to MHC molecules is one of the crucial steps (Roomp et al. <xref ref-type="bibr" rid="CR45">2010</xref>). Using NetMHC 3.2 server, we predicted a total of 65 unique epitopes from the consensus sequences dataset of E1 protein. Likewise, 8 from E2, 5 from E6 and 2 unique epitopes from E7 protein consensus sequence datasets were predicted by the server with either strong or weak binding affinity (Supplementary Table&#x000a0;1&#x02013;4). As epitopes were predicted from the consensus conserved peptide fragments of protein datasets through NetMHC 3.2 server, there are chances that some of the epitopes may not show 100&#x000a0;% identity with any of the protein in the datasets due to presence of consensus amino acid residues substituted during conservancy analysis. To verify this, epitopes were realigned with the primary protein datasets of E1, E2, E6 and E7 proteins collected for various high-risk HPV strains. Those epitopes which were not completely mapped with any of the primary protein sequences of high-risk HPV strains were filtered out. In this process, 16 epitopes from E1, 2 from E2, 2 from E6 and both the epitopes from E7 datasets were discarded. To predict the long immunogenic peptide fragments, all the overlapping epitopes were merged (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In total, 15 immunogenic conserved peptide fragments were identified, of which 11 fragments were from E1, 3 from E2 and 1 fragment was from E6 protein dataset of high-risk HPV strains.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Immunogenic peptide fragments identified from selected protein datasets of high-risk HPV strains</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">HPV protein fragment </th><th align="left" rowspan="2">Immunogenic peptide sequence</th><th align="left" rowspan="2">HLA alleles targeted</th><th align="left" rowspan="2">High-risk HPV strains mapped</th></tr><tr><th align="left">Protein name</th><th align="left">Immunogenic peptide fragment</th></tr></thead><tbody><tr><td align="left" rowspan="11">E1</td><td align="left">E1-F1</td><td align="left">DSGYGNTEV</td><td align="left">HLA-A6802</td><td align="left">16, 31, 33, 58, 73</td></tr><tr><td align="left">E1-F2</td><td align="left">LVRPFKSDK</td><td align="left">HLA-A0301,HLA-A3001</td><td align="left">33, 58</td></tr><tr><td align="left">E1-F3</td><td align="left">CMLIEPPKL</td><td align="left">HLA-A0201,HLA-A0211,HLA-A0212,HLA-A0216,HLA-A0219,HLA-A0250</td><td align="left">45, 59</td></tr><tr><td align="left">E1-F4</td><td align="left">ALYWYRTGISNISEV</td><td align="left">HLA-A0201,HLA-A0202,HLA-A0203,HLA-A0206,HLA-A0211,HLA-A0212,HLA-A0216,HLA-A0250,HLA-A2301,HLA-A2403,HLA-A6802</td><td align="left">16, 18, 39, 45, 68</td></tr><tr><td align="left">E1-F5</td><td align="left">DLSEMVQWAFD</td><td align="left">HLA-A0203,HLA-A0211,HLA-A0216,HLA-A0219,HLA-A0250,HLA-B4501</td><td align="left">18, 33, 35</td></tr><tr><td align="left">E1-F6</td><td align="left">NSNAAAFLKSNCQAKYVKDCATMCRHYKRAQKRQMSMSQWIK</td><td align="left">HLA-A0201, HLA-A0202,HLA-A0203,HLA-A0206,HLA-A2402,HLA-A3201,HLA-B1501,HLA-B1503,HLA-B2705,HLA-A0301,HLA-A1101,HLA-A6801,HLA-B1503,HLA-A3001,HLA-B0702,HLA-B0801,HLA-B1517,HLA-B5801,HLA-A3101,HLA-A3301,HLA-A2301,HLA-A2403,HLA-A3002,HLA-A6801</td><td align="left">39, 59, 16, 68, 45, 31, 35, 52, 69, 39, 51, 82, 18</td></tr><tr><td align="left">E1-F7</td><td align="left">WRPIVQFLRYQGVEFI</td><td align="left">HLA-B2705,HLA-B3501, HLA-B5301,HLA-A0203,HLA-A0206,HLA-A0211,HLA-A0216,HLA-A0250, HLA-B1503</td><td align="left">18, 39, 45, 58, 68, 56, 59</td></tr><tr><td align="left">E1-F8</td><td align="left">PKKNCIVIYGPANTGKSYFGMSLIHFL</td><td align="left">HLA-A0201,HLA-A0202,HLA-A0206,HLA-A0211,HLA-A0216,HLA-A6802,HLA-A6901,HLA-B3901,HLA-A2301,HLA-A2402, HLA-A2403,HLA-A2902,HLA-B1501,HLA-A0203,HLA-A3001,HLA-A3201,HLA-B1517,HLA-B5801,HLA-B1503,HLA-A2603,HLA-B1502,HLA-B3501,HLA-B1503</td><td align="left">18, 58, 31, 33, 52, 59, 45, 39</td></tr><tr><td align="left">E1-F9</td><td align="left">VQLKCPPLLITSNI</td><td align="left">HLA-B5301,HLA-A0203,HLA-A0201,HLA-A0206,HLA-B1503,HLA-B3901,HLA-B4801</td><td align="left">16, 31, 33, 35, 51</td></tr><tr><td align="left">E1-F10</td><td align="left">RWPYLHSRLTVF</td><td align="left">HLA-A0202,HLA-A0203,HLA-A0211,HLA-A0250,HLA-B0801,HLA-B1501,HLA-B1502,HLA-B1503,HLA-B1517,HLA-B3501,HLA-B5401,HLA-A2402,HLA-A2403</td><td align="left">31, 33, 52, 58, 68</td></tr><tr><td align="left">E1-F11</td><td align="left">KNWKSFFSRTWSRL</td><td align="left">HLA-A2301,HLA-A2403,HLA-A1101,HLA-A3101,HLA-A3301,HLA-A6801,HLA-B1503,HLA-A3101</td><td align="left">16, 31, 33, 35, 52, 58</td></tr><tr><td align="left" rowspan="3">E2</td><td align="left">E2-F1</td><td align="left">ETLSQRLNVCQDKI</td><td align="left">HLA-A0202,HLA-A0203,HLA-A0212,HLA-A0219,HLA-A6802,HLA-A6901</td><td align="left">16, 31</td></tr><tr><td align="left">E2-F2</td><td align="left">ECAIFYKAR</td><td align="left">HLA-A6801</td><td align="left">69</td></tr><tr><td align="left">E2-F3</td><td align="left">QAIELQMALESL</td><td align="left">HLA-A0202,HLA-A0211,HLA-A0219,HLA-A0250,HLA-B4002,HLA-A0206,HLA-A6802,HLA-A6901,HLA-B3501,HLA-B3901</td><td align="left">39, 59, 68</td></tr><tr><td align="left">E6</td><td align="left">E6-F1</td><td align="left">FYSKISEYRHY</td><td align="left">HLA-A2602,HLA-B1503,HLA-B1517,HLA-A2403,HLA-A3101,HLA-A3301,HLA-A6801</td><td align="left">16, 33, 35, 52, 58</td></tr></tbody></table></table-wrap>
</p><p>To further identify the minimal set of immunogenic peptide fragment datasets to target all the high-risk HPV strains, we discarded those peptide fragments where the targeted HLA alleles and high-risk HPV strains were the subsets of other highly efficient peptide fragments shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. In this process, immunogenic peptide sequence ECAIFYKAR (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>: E2-F2) from the high-risk HPV strain 69 was filtered out as it can be considered the subset of immunogenic fragment E1-F6 which is also present in type 69 HPV strain and also target the same allele besides its affinity with other alleles. Thus, in total, we have identified a peptide pool of 14 sequences that might be effective to generate immunogenic responses against any of the high-risk HPV strains. The interaction map of immunogenic peptide fragments, their HLA allelic responses and their presence in various HPV high-risk strains are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. To discard peptide fragments that can be recognized as self protein for the immune system we performed BLAST screening of all the 14 immunogenic peptides with entire human proteome. None of the peptide was similar to human proteome. We finally performed the population coverage analysis of generated immunogenic peptide pool using population coverage analysis tool available at IEDB server (<ext-link ext-link-type="uri" xlink:href="http://tools.immuneepitope.org/tools/population">http://tools.immuneepitope.org/tools/population</ext-link>). The percentage population coverage of the immunogenic peptide pool generated from the current analysis in various ethnicities is shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Illustration of the interaction network of immunogenic peptide fragments, High-risk HPV strains which contributed for the formation of these fragments and MHC class I alleles are shown. Edges with<italic> different colors</italic> represent various immunogenic peptide fragments as shown in figure legends. High-risk HPV strains are shown in<italic> green hexagon</italic> in the<italic> inner circle</italic> and HLA alleles on the<italic> outer circle</italic> with<italic> red color</italic>. From the figure it is clear that few alleles (e.g. A2602, A2603, A2902, A3002, B0702, B1502, B4002, B4501, B4801, B5401) are targeted by only one immunogenic peptide fragments, while majority of HLA alleles (A0201, A0202, A0203, A0206, A0211, A0212, A0216, A0219, A0250, A0301, A1101, A2301, A2402, A2403, A3001, A3101, A3201, A3301, A6801, A6802, A6901, B0801, B1501, B1503, B1517, B2705, B3501, B3901, B5301, B5801) are targeted by most of the immunogenic peptides selected in this study</p></caption><graphic xlink:href="13205_2015_352_Fig1_HTML" id="MO2"/></fig>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Population coverage analysis for immunogenic peptide pooled in various ethnicities </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">High-risk HPV strain</th><th align="left" colspan="10">Percentage population coverage in various ethnicities</th></tr><tr><th align="left">Australia (%)</th><th align="left">Europe (%)</th><th align="left">North Africa (%)</th><th align="left">North America (%)</th><th align="left">North-East Asia (%)</th><th align="left">Oceania (%)</th><th align="left">South America (%)</th><th align="left">South-East Asia (%)</th><th align="left">South-West Asia (%)</th><th align="left">Sub-Saharan Africa (%)</th></tr></thead><tbody><tr><td align="left">TYPE 16</td><td char="." align="char">81.24</td><td char="." align="char">94.35</td><td char="." align="char">63.21</td><td char="." align="char">95.17</td><td char="." align="char">69.98</td><td char="." align="char">88.73</td><td char="." align="char">53.15</td><td char="." align="char">86.72</td><td char="." align="char">79.18</td><td char="." align="char">85.14</td></tr><tr><td align="left">TYPE 18</td><td char="." align="char">65.40</td><td char="." align="char">74.28</td><td char="." align="char">50.63</td><td char="." align="char">91.46</td><td char="." align="char">60.15</td><td char="." align="char">76.33</td><td char="." align="char">53.56</td><td char="." align="char">73.07</td><td char="." align="char">64.57</td><td char="." align="char">76.17</td></tr><tr><td align="left">TYPE 31</td><td char="." align="char">81.33</td><td char="." align="char">95.31</td><td char="." align="char">65.99</td><td char="." align="char">96.89</td><td char="." align="char">76.13</td><td char="." align="char">91.12</td><td char="." align="char">54.37</td><td char="." align="char">89.97</td><td char="." align="char">81.73</td><td char="." align="char">86.83</td></tr><tr><td align="left">TYPE 33</td><td char="." align="char">80.85</td><td char="." align="char">92.30</td><td char="." align="char">64.35</td><td char="." align="char">95.03</td><td char="." align="char">74.60</td><td char="." align="char">91.06</td><td char="." align="char">53.76</td><td char="." align="char">89.76</td><td char="." align="char">80.19</td><td char="." align="char">83.36</td></tr><tr><td align="left">TYPE 35</td><td char="." align="char">81.24</td><td char="." align="char">94.15</td><td char="." align="char">62.30</td><td char="." align="char">95.14</td><td char="." align="char">69.90</td><td char="." align="char">88.73</td><td char="." align="char">52.88</td><td char="." align="char">86.69</td><td char="." align="char">78.19</td><td char="." align="char">82.91</td></tr><tr><td align="left">TYPE 39</td><td char="." align="char">81.29</td><td char="." align="char">95.30</td><td char="." align="char">65.99</td><td char="." align="char">95.88</td><td char="." align="char">71.40</td><td char="." align="char">89.45</td><td char="." align="char">54.17</td><td char="." align="char">87.99</td><td char="." align="char">81.60</td><td char="." align="char">86.83</td></tr><tr><td align="left">TYPE 45</td><td char="." align="char">81.29</td><td char="." align="char">95.30</td><td char="." align="char">65.99</td><td char="." align="char">95.88</td><td char="." align="char">71.40</td><td char="." align="char">89.45</td><td char="." align="char">54.17</td><td char="." align="char">87.99</td><td char="." align="char">81.60</td><td char="." align="char">86.83</td></tr><tr><td align="left">TYPE 51</td><td char="." align="char">81.24</td><td char="." align="char">94.04</td><td char="." align="char">56.96</td><td char="." align="char">95.04</td><td char="." align="char">68.92</td><td char="." align="char">88.73</td><td char="." align="char">48.71</td><td char="." align="char">86.55</td><td char="." align="char">77.50</td><td char="." align="char">79.99</td></tr><tr><td align="left">TYPE 52</td><td char="." align="char">81.29</td><td char="." align="char">95.30</td><td char="." align="char">65.99</td><td char="." align="char">95.88</td><td char="." align="char">74.42</td><td char="." align="char">89.58</td><td char="." align="char">54.17</td><td char="." align="char">88.72</td><td char="." align="char">81.51</td><td char="." align="char">86.83</td></tr><tr><td align="left">TYPE 56</td><td char="." align="char">0.49</td><td char="." align="char">17.12</td><td char="." align="char">8.63</td><td char="." align="char">40.71</td><td char="." align="char">18.50</td><td char="." align="char">2.56</td><td char="." align="char">8.86</td><td char="." align="char">14.30</td><td char="." align="char">15.98</td><td char="." align="char">23.50</td></tr><tr><td align="left">TYPE 58</td><td char="." align="char">80.85</td><td char="." align="char">92.75</td><td char="." align="char">59.07</td><td char="." align="char">95.17</td><td char="." align="char">74.34</td><td char="." align="char">89.51</td><td char="." align="char">53.56</td><td char="." align="char">88.50</td><td char="." align="char">79.96</td><td char="." align="char">80.90</td></tr><tr><td align="left">TYPE 59</td><td char="." align="char">81.29</td><td char="." align="char">95.30</td><td char="." align="char">65.99</td><td char="." align="char">95.88</td><td char="." align="char">71.40</td><td char="." align="char">89.45</td><td char="." align="char">54.17</td><td char="." align="char">87.99</td><td char="." align="char">81.60</td><td char="." align="char">86.83</td></tr><tr><td align="left">TYPE 68</td><td char="." align="char">81.29</td><td char="." align="char">95.30</td><td char="." align="char">65.99</td><td char="." align="char">95.88</td><td char="." align="char">73.51</td><td char="." align="char">89.58</td><td char="." align="char">54.17</td><td char="." align="char">88.47</td><td char="." align="char">81.60</td><td char="." align="char">86.83</td></tr><tr><td align="left">TYPE 69</td><td char="." align="char">80.40</td><td char="." align="char">93.85</td><td char="." align="char">55.85</td><td char="." align="char">93.45</td><td char="." align="char">65.25</td><td char="." align="char">86.26</td><td char="." align="char">44.60</td><td char="." align="char">83.12</td><td char="." align="char">77.29</td><td char="." align="char">79.75</td></tr><tr><td align="left">TYPE 73</td><td char="." align="char">0.00</td><td char="." align="char">1.58</td><td char="." align="char">9.82</td><td char="." align="char">0.92</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td><td char="." align="char">0.00</td><td char="." align="char">0.03</td><td char="." align="char">1.63</td><td char="." align="char">14.68</td></tr><tr><td align="left">TYPE 82</td><td char="." align="char">80.40</td><td char="." align="char">93.85</td><td char="." align="char">55.85</td><td char="." align="char">93.45</td><td char="." align="char">65.25</td><td char="." align="char">86.26</td><td char="." align="char">44.60</td><td char="." align="char">83.12</td><td char="." align="char">77.29</td><td char="." align="char">79.75</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>In the post-genomic era, strategies of vaccine development have progressed dramatically from traditional Pasteur&#x02019;s principles of isolating, inactivating and injecting the causative agent of an infectious disease, to reverse vaccinology that initiates from in silico analysis of the genome information (Akhoon et al. <xref ref-type="bibr" rid="CR2">2011</xref>). In silico works have attracted considerable attention of experimental biologists for rapid screening and identification of probable vaccine candidates (Sakib et al. <xref ref-type="bibr" rid="CR46">2014</xref>; Sharma et al. <xref ref-type="bibr" rid="CR49">2013</xref>; Hasan et al. <xref ref-type="bibr" rid="CR24">2013</xref>; Oany et al. <xref ref-type="bibr" rid="CR36">2014</xref>). The availability of fully sequenced proteome from high-risk HPV strains provide an opportunity for computer-aided screening of reliable peptide-based therapeutic vaccines candidates among billions of possible immune-active peptides.</p><p>We extracted high-risk HPV proteome for 8 HPV specific proteins designated as E- (E1, E2, E4, E5, E6 and E7) or L-type (L1 and L2) according to their expression in early or late differentiation stage of the epithelium (Burd <xref ref-type="bibr" rid="CR10">2003</xref>; Rautava and Syrj&#x000e4;nen <xref ref-type="bibr" rid="CR43">2012</xref>). The early secretary proteins expressed during early differentiating stage of epithelium development in all the 16 high-risk HPV strains. Since the E5 protein of HPV has previously been reported as inducer of down-regulation of MHC class I, we ignored E5 protein in the current analysis. Moreover, E2&#x02013;E5 region has been shown to be lost when the episomal HPV DNA integrates into host chromosome; using E2&#x02013;E5 proteins as vaccine candidates may be futile. However, since E1 and E2 are expressed in higher levels than E6 and E7 early in the progress of an HPV infection, it may be assumed that these proteins may considered as good targets for vaccine designing to treat early stages of disease (Burd <xref ref-type="bibr" rid="CR10">2003</xref>). Therefore, E2 protein was included for epitope-based vaccine designing in the present study along with E1, E6 and E7 protein. Based on our computational workflow, we generated a pool of 14 peptide fragments with length varying from 9 to 43 amino acid residues to provide immunogenic responses against all the high-risk HPV strains. The hallmark of the immune system is its ability to recognize and distinguish between self and non-self. T-cells do this task by recognizing peptides that are bound to MHC receptors. Epitopes are usually thought to be derived from non-self protein antigen that interacts with antibodies or T-cell receptors, thereby activating an immune response. Epitopes are usually thought to be derived from non-self protein antigen that interacts with antibodies or T-cell receptors, thereby activating an immune response. Also the antigen&#x02013;antibody interaction is reversible, therefore, weak interactions often lead to cross-reactivity of antigens. The main reasons of cross-reactivity are either the homologous proteins that are conserved throughout the development and expressed by both the infectious agent and the host or the viral proteins that share short regions of amino acid sequence similarity with a non-homologous host protein. Therefore, to exclude the epitopes those are conserved between the pathogen and the host, we performed sequence alignment of the selected pool of 14 immunogenic peptides with entire human proteome. We did not observe similarity between any of the selected immunogenic peptide fragments with human proteome, we also discarded epitopes showing weak interactions with HLA alleles. Thus we believe that all the 14 sequences together will form the best peptide pool to generated immunogenic responses against any of the high-risk HPV&#x000a0;strains infection.</p><p>Population coverage analysis for a given set of immunogenic peptides is important to determine their efficacy as the frequency of expression of their targeted HLA alleles varies across ethnicities. With the population coverage analysis, we concluded that least immunogenic response is shown by HPV strain 73 followed by strain 56 in almost all the ethnicities. Thus, the data indicate that the generated peptide fragments pool will provide very weak protection against HPV Type 73 and 56. The best response is shown by North American population for all the HPV high-risk strains based on the HLA alleles frequency data. Overall, we proposed the pool of 14 immunogenic peptide fragments with length ranging from 9 to 43 amino acid residues to provide the protection against all the HPV high-risk strains except Type 73 and 56 in all the ethnicities.</p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusion</title><p>Immunoinformatics has changed the paradigm of ancient vaccinology since it is recently emerged as a critical field for accelerating immunology research (Baloria et al. <xref ref-type="bibr" rid="CR5">2012</xref>). Moreover, the immunoinformatics techniques applied to T-cells have advanced to a greater degree than those dealing with B-cells. Indeed, it is now a common practice to identify the vaccine candidates using in silico approaches before being subjected to in vitro confirmatory studies (Gupta et al. <xref ref-type="bibr" rid="CR20">2009</xref>; Ranjbar et al. <xref ref-type="bibr" rid="CR42">2015</xref>). The major objective of our study was to identify an immunogenic peptide pool containing epitopes that can be effective against all the high-risk HPV strains circulating globally. Some cross-protections were already observed in case of previously identified vaccines. Such as, Cervarix vaccine which was initially designed by targeting HPV 16 and 18 strains but later found to provide additional cross-protections against HPV 31, 33 and 45 strains. However, most of the high-risk HPV strains were evolved by accumulating random mutations in the epitopes recognizing regions and therefore many of the high-risk strains are not effectively targeted by available HPV vaccines. Therefore, we used the consensus epitopes extracted from highly conserved regions of E1, E2, E6 and E7 proteins from all the high-risk HPV strains identified so far. The vaccine formulated by the proposed peptide pool can alert the body&#x02019;s immune system to generate immunization memory cells upon injecting. Subsequently, as these are MHC class I epitopes, the proteasomal degradation machineries can degrade the whole vaccine and release these conserved epitopes in host. Furthermore, because of the conserved nature of the epitopes the immune system will be trained to recognize these epitopes in case of HPV infection by any high-risk strains and thus can provide the cross-protection. Using the computational workflow presented in this manuscript, we identified 14 conserved immunogenic peptide fragments from 4 early proteins (E1, E2, E6 and E7) of 16 high-risk HPV types providing CD8+ responses which can be validated experimentally for the designing of an universal vaccine against all the high-risk HPV strains.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec11"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13205_2015_352_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 36&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13205_2015_352_MOESM2_ESM.docx"><caption><p>Supplementary material 2 (DOCX 16&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13205_2015_352_MOESM3_ESM.docx"><caption><p>Supplementary material 3 (DOCX 15&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="13205_2015_352_MOESM4_ESM.docx"><caption><p>Supplementary material 4 (DOCX 14&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="13205_2015_352_MOESM5_ESM.docx"><caption><p>Supplementary material 5 (DOCX 35&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HPV</term><def><p>Human papilloma virus</p></def></def-item><def-item><term>CTL</term><def><p>Cytotoxic T-cell</p></def></def-item><def-item><term>PVS</term><def><p>Protein variability server</p></def></def-item><def-item><term>MHC</term><def><p>Major histocompatibility complex</p></def></def-item><def-item><term>TCR</term><def><p>T-cell receptor</p></def></def-item><def-item><term>HLA</term><def><p>Human leukocyte antigen</p></def></def-item><def-item><term>PSSMs</term><def><p>Position specific scoring matrices</p></def></def-item><def-item><term>ANN</term><def><p>Artificial neural network</p></def></def-item></def-list></glossary><fn-group><fn><p>Krishna P. Singh and Neeraj Verma have contributed equally to this article.</p></fn></fn-group><ack><p>KPS, BAA, SKG acknowledge financial support from Council of Scientific and Industrial Research (CSIR) India network project GENESIS (BSC0121) and INDEPTH (BSC0111), NV and VB was financially supported by Society for Biological Research &#x00026; Rural Development, India.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p>The authors declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Navabi</surname><given-names>H</given-names></name><name><surname>Jasani</surname><given-names>B</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Fiander</surname><given-names>A</given-names></name><name><surname>Evan</surname><given-names>AS</given-names></name><name><surname>Donningerc</surname><given-names>C</given-names></name><name><surname>Mason</surname><given-names>M</given-names></name></person-group><article-title>Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R)</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>787</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00599-6</pub-id><pub-id pub-id-type="pmid">12531360</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhoon</surname><given-names>BA</given-names></name><name><surname>Slathia</surname><given-names>PS</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Verma</surname><given-names>V</given-names></name></person-group><article-title>In silico identification of novel protective VSG antigens expressed by Trypanosoma brucei and an effort for designing a highly immunogenic DNA vaccine using IL-12 as adjuvant</article-title><source>Microb Pathog</source><year>2011</year><volume>51</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2011.01.011</pub-id><pub-id pub-id-type="pmid">21349321</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apweiler</surname><given-names>R</given-names></name><name><surname>Bairoch</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Barker</surname><given-names>WC</given-names></name><name><surname>Boeckmann</surname><given-names>B</given-names></name><name><surname>Ferro</surname><given-names>S</given-names></name><name><surname>Gasteiger</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Magrane</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>MJ</given-names></name><name><surname>Natale</surname><given-names>DA</given-names></name><name><surname>O&#x02019;Donovan</surname><given-names>C</given-names></name><name><surname>Redaschi</surname><given-names>N</given-names></name><name><surname>Yeh</surname><given-names>LS</given-names></name></person-group><article-title>UniProt: the universal protein knowledgebase</article-title><source>Nucleic Acids Res</source><year>2004</year><volume>32</volume><fpage>D115</fpage><lpage>D119</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh131</pub-id><pub-id pub-id-type="pmid">14681372</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ault</surname><given-names>KA</given-names></name><name><surname>Giuliano</surname><given-names>AR</given-names></name><name><surname>Edwards</surname><given-names>RP</given-names></name><name><surname>Tamms</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>LL</given-names></name><name><surname>Smith</surname><given-names>JF</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Allende</surname><given-names>M</given-names></name><name><surname>Taddeo</surname><given-names>FJ</given-names></name><name><surname>Skulsky</surname><given-names>D</given-names></name><name><surname>Barr</surname><given-names>E</given-names></name></person-group><article-title>A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3004</fpage><lpage>3007</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.02.020</pub-id><pub-id pub-id-type="pmid">15297048</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baloria</surname><given-names>U</given-names></name><name><surname>Akhoon</surname><given-names>BA</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>V</given-names></name></person-group><article-title>In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer</article-title><source>Amino Acids</source><year>2012</year><volume>42</volume><fpage>1349</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1007/s00726-010-0830-x</pub-id><pub-id pub-id-type="pmid">21229277</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baseman</surname><given-names>JG</given-names></name><name><surname>Koutsky</surname><given-names>LA</given-names></name></person-group><article-title>The epidemiology of human papillomavirus infections</article-title><source>In J Clin Virol</source><year>2005</year><volume>32</volume><fpage>S16</fpage><lpage>S24</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.12.008</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>HU</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>van Doorslaer</surname><given-names>K</given-names></name><name><surname>zur Hausen</surname><given-names>H</given-names></name><name><surname>de Villiers</surname><given-names>EM</given-names></name></person-group><article-title>Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments</article-title><source>Virology</source><year>2010</year><volume>401</volume><fpage>70</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.02.002</pub-id><pub-id pub-id-type="pmid">20206957</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bet</surname><given-names>A</given-names></name><name><surname>Maze</surname><given-names>EA</given-names></name><name><surname>Bansal</surname><given-names>A</given-names></name><name><surname>Sterrett</surname><given-names>S</given-names></name><name><surname>Gross</surname><given-names>A</given-names></name><name><surname>Graff-Dubois</surname><given-names>S</given-names></name><name><surname>Samri</surname><given-names>A</given-names></name><name><surname>Guihot</surname><given-names>A</given-names></name><name><surname>Katlama</surname><given-names>C</given-names></name><name><surname>Theodorou</surname><given-names>I</given-names></name><name><surname>Mesnard</surname><given-names>JM</given-names></name><name><surname>Moris</surname><given-names>A</given-names></name><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Cardinaud</surname><given-names>S</given-names></name></person-group><article-title>The HIV-1 Antisense Protein (ASP) induces CD8 T cell responses during chronic infection</article-title><source>Retrovirolo</source><year>2015</year><volume>10</volume><fpage>12</fpage><lpage>15</lpage></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braaten</surname><given-names>KP</given-names></name><name><surname>Laufer</surname><given-names>MR</given-names></name></person-group><article-title>Human Papillomavirus (HPV), HPV-related disease, and the HPV vaccine</article-title><source>Rev Obstet Gynecol</source><year>2008</year><volume>1</volume><fpage>2</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">18701931</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burd</surname><given-names>EM</given-names></name></person-group><article-title>Human papillomavirus and cervical cancer</article-title><source>Clin Microbiol Rev</source><year>2003</year><volume>16</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.1.1-17.2003</pub-id><pub-id pub-id-type="pmid">12525422</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LP</given-names></name><name><surname>Thomas</surname><given-names>EK</given-names></name><name><surname>Hu</surname><given-names>SL</given-names></name><name><surname>Hellstr&#x000f6;m</surname><given-names>I</given-names></name><name><surname>Hellstr&#x000f6;m</surname><given-names>KE</given-names></name></person-group><article-title>Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.1.110</pub-id><pub-id pub-id-type="pmid">1846033</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>Y</given-names></name><name><surname>Einstein</surname><given-names>MH</given-names></name><name><surname>Gostout</surname><given-names>BS</given-names></name><name><surname>Herzog</surname><given-names>TJ</given-names></name><name><surname>Massad</surname><given-names>LS</given-names></name><name><surname>Rader</surname><given-names>JS</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name></person-group><article-title>Cervical cancer prevention in the era of prophylactic vaccines, a preview for gynecologic oncologists</article-title><source>Gynecol Oncol</source><year>2006</year><volume>102</volume><fpage>552</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2006.07.022</pub-id><pub-id pub-id-type="pmid">16979432</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dames</surname><given-names>DN</given-names></name><name><surname>Blackman</surname><given-names>Elizabeth</given-names></name><name><surname>Butler</surname><given-names>Raleigh</given-names></name><name><surname>Taioli</surname><given-names>Emanuela</given-names></name><name><surname>Eckstein</surname><given-names>Stacy</given-names></name><name><surname>Devarajan</surname><given-names>Karthik</given-names></name></person-group><article-title>High-risk cervical human papillomavirus infections among human immunodeficiency virus-positive women in the Bahamas</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e85429</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0085429</pub-id><pub-id pub-id-type="pmid">24465558</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bruijn</surname><given-names>ML</given-names></name><name><surname>Schuurhuis</surname><given-names>DH</given-names></name><name><surname>Vierboom</surname><given-names>MP</given-names></name><name><surname>Vermeulen</surname><given-names>H</given-names></name><name><surname>de Cock</surname><given-names>KA</given-names></name><name><surname>Ooms</surname><given-names>ME</given-names></name><name><surname>Ressing</surname><given-names>ME</given-names></name><name><surname>Toebes</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>KL</given-names></name><name><surname>Drijfhout</surname><given-names>JW</given-names></name><name><surname>Ottenhoff</surname><given-names>TH</given-names></name><name><surname>Offringa</surname><given-names>R</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name></person-group><article-title>Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>724</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">9485027</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunne</surname><given-names>EF</given-names></name><name><surname>Unger</surname><given-names>ER</given-names></name><name><surname>Sternberg</surname><given-names>M</given-names></name><name><surname>McQuillan</surname><given-names>G</given-names></name><name><surname>Swan</surname><given-names>DC</given-names></name><name><surname>Patel</surname><given-names>SS</given-names></name><name><surname>Markowitz</surname><given-names>LE</given-names></name></person-group><article-title>Prevalence of HPV infection among females in the United States</article-title><source>JAMA</source><year>2007</year><volume>297</volume><fpage>813</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1001/jama.297.8.813</pub-id><pub-id pub-id-type="pmid">17327523</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiben</surname><given-names>GL</given-names></name><name><surname>Velders</surname><given-names>MP</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name></person-group><article-title>The cell-mediated immune response to human papillomavirus-induced cervical cancer, implications for immunotherapy</article-title><source>Adv Cancer Res</source><year>2002</year><volume>86</volume><fpage>113</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/S0065-230X(02)86004-3</pub-id><pub-id pub-id-type="pmid">12374277</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feltkamp</surname><given-names>MC</given-names></name><name><surname>Smits</surname><given-names>HL</given-names></name><name><surname>Vierboom</surname><given-names>MP</given-names></name><name><surname>Minnaar</surname><given-names>RP</given-names></name><name><surname>de Jongh</surname><given-names>BM</given-names></name><name><surname>Drijfhout</surname><given-names>JW</given-names></name><name><surname>ter Schegget</surname><given-names>J</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name></person-group><article-title>Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells</article-title><source>Eur J Immunol</source><year>1993</year><volume>23</volume><fpage>2242</fpage><lpage>2249</lpage><pub-id pub-id-type="doi">10.1002/eji.1830230929</pub-id><pub-id pub-id-type="pmid">7690326</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fife</surname><given-names>KH</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Koutsky</surname><given-names>LA</given-names></name><name><surname>Barr</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Schiff</surname><given-names>MA</given-names></name><name><surname>Kiviat</surname><given-names>NB</given-names></name><name><surname>Jansen</surname><given-names>KU</given-names></name><name><surname>Barber</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>JF</given-names></name><name><surname>Tadesse</surname><given-names>A</given-names></name><name><surname>Giacoletti</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>PR</given-names></name><name><surname>Suhr</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name></person-group><article-title>Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2943</fpage><lpage>2952</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.11.058</pub-id><pub-id pub-id-type="pmid">15246631</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankild</surname><given-names>S</given-names></name><name><surname>de Boer</surname><given-names>RJ</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Kesmir</surname><given-names>C</given-names></name></person-group><article-title>Amino acid similarity accounts for T cell cross-reactivity and for &#x0201c;holes&#x0201d; in the T cell repertoire</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e1831</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0001831</pub-id><pub-id pub-id-type="pmid">18350167</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Akhoon</surname><given-names>BA</given-names></name></person-group><article-title>In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer</article-title><source>Vaccine</source><year>2009</year><volume>28</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.09.095</pub-id><pub-id pub-id-type="pmid">19799841</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Smita</surname><given-names>S</given-names></name><name><surname>Sarangi</surname><given-names>AN</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Akhoon</surname><given-names>BA</given-names></name><name><surname>Rahman</surname><given-names>Q</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name></person-group><article-title>In silico CD4&#x000a0;+&#x000a0;T-cell epitope prediction and HLA distribution analysis for the potential proteins of <italic>Neisseria meningitidis</italic> Serogroup B&#x02014;a clue for vaccine development</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7092</fpage><lpage>7097</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.005</pub-id><pub-id pub-id-type="pmid">20716448</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Akhoon</surname><given-names>BA</given-names></name><name><surname>Smita</surname><given-names>S</given-names></name><name><surname>Schmitz</surname><given-names>U</given-names></name><name><surname>Wolkenhauer</surname><given-names>O</given-names></name><name><surname>Vera</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name></person-group><article-title>Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase</article-title><source>Infect Genet Evol</source><year>2011</year><volume>11</volume><fpage>308</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2010.10.013</pub-id><pub-id pub-id-type="pmid">21094280</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Akhoon</surname><given-names>BA</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Grabe</surname><given-names>N</given-names></name></person-group><article-title><italic>In silico</italic> accelerated identification of structurally conserved CD8+ and CD4+ T-cell epitopes in high-risk HPV types</article-title><source>Infect Genet Evol</source><year>2012</year><volume>12</volume><fpage>1513</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.02.022</pub-id><pub-id pub-id-type="pmid">22634276</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>MA</given-names></name><name><surname>Hossain</surname><given-names>M</given-names></name><name><surname>Alam</surname><given-names>MJ</given-names></name></person-group><article-title>A computational assay to design an epitope-based Peptide vaccine against saint louis encephalitis virus</article-title><source>Bioinform Biol Insights</source><year>2013</year><volume>7</volume><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.4137/BBI.S13402</pub-id><pub-id pub-id-type="pmid">24324329</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henikoff</surname><given-names>S</given-names></name><name><surname>Henikoff</surname><given-names>JG</given-names></name></person-group><article-title>Amino acid substitution matrices from protein blocks</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>10915</fpage><lpage>10919</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.22.10915</pub-id><pub-id pub-id-type="pmid">1438297</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herzog</surname><given-names>TJ</given-names></name><name><surname>Wright</surname><given-names>JD</given-names></name></person-group><article-title>The impact of cervical cancer on quality of life-the components and means for management</article-title><source>Gynecol Oncol</source><year>2007</year><volume>107</volume><fpage>572</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2007.09.019</pub-id><pub-id pub-id-type="pmid">17963826</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>WK</given-names></name><name><surname>Roden</surname><given-names>RB</given-names></name></person-group><article-title>The future of vaccines for cervical cancer</article-title><source>Gynecol Oncol</source><year>2008</year><volume>109</volume><fpage>S48</fpage><lpage>S56</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2008.01.004</pub-id><pub-id pub-id-type="pmid">18482559</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Litwin</surname><given-names>S</given-names></name><name><surname>Jores</surname><given-names>R</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Weisbuch</surname><given-names>G</given-names></name></person-group><source>Theoretical and experimental insights into immunology</source><year>1992</year><publisher-loc>Berlin</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>TY</given-names></name><name><surname>Hussein</surname><given-names>WM</given-names></name><name><surname>Toth</surname><given-names>I</given-names></name><name><surname>Skwarczynski</surname><given-names>M</given-names></name></person-group><article-title>Advances in peptide-based human papillomavirus therapeutic vaccines</article-title><source>Curr Top Med Chem</source><year>2012</year><volume>12</volume><fpage>1581</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.2174/156802612802652402</pub-id><pub-id pub-id-type="pmid">22827526</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowitz</surname><given-names>LE</given-names></name><name><surname>Dunne</surname><given-names>EF</given-names></name><name><surname>Saraiya</surname><given-names>M</given-names></name><name><surname>Lawson</surname><given-names>HW</given-names></name><name><surname>Chesson</surname><given-names>H</given-names></name><name><surname>Unger</surname><given-names>ER</given-names></name></person-group><article-title>Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title><source>MMWR Recomm Rep</source><year>2007</year><volume>23</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17380109</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin-Drubin</surname><given-names>ME</given-names></name></person-group><article-title>Human papillomaviruses and non-melanoma skin cancer</article-title><source>Semin Oncol</source><year>2015</year><volume>42</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2014.12.032</pub-id><pub-id pub-id-type="pmid">25843732</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meijer</surname><given-names>CJ</given-names></name><name><surname>Heideman</surname><given-names>DA</given-names></name><name><surname>Berkhof</surname><given-names>H</given-names></name><name><surname>Snijders</surname><given-names>PJ</given-names></name></person-group><article-title>Prevention of cervical cancer: where immunology meets diagnostics</article-title><source>Immunol Lett</source><year>2009</year><volume>122</volume><fpage>126</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2008.11.011</pub-id><pub-id pub-id-type="pmid">19100775</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meiring</surname><given-names>TL</given-names></name><name><surname>Salimo</surname><given-names>AT</given-names></name><name><surname>Coetzee</surname><given-names>B</given-names></name><name><surname>Maree</surname><given-names>HJ</given-names></name><name><surname>Moodley</surname><given-names>J</given-names></name><name><surname>Hitzeroth</surname><given-names>II</given-names></name><name><surname>Freeborough</surname><given-names>MJ</given-names></name><name><surname>Rybicki</surname><given-names>EP</given-names></name><name><surname>Williamson</surname><given-names>AL</given-names></name></person-group><article-title>Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits</article-title><source>Virol J</source><year>2012</year><volume>9</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-9-164</pub-id><pub-id pub-id-type="pmid">22897914</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>N</given-names></name><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>de Sanjos&#x000e9;</surname><given-names>S</given-names></name><name><surname>Herrero</surname><given-names>R</given-names></name><name><surname>Castellsagu&#x000e9;</surname><given-names>X</given-names></name><name><surname>Shah</surname><given-names>KV</given-names></name><name><surname>Snijders</surname><given-names>PJ</given-names></name><name><surname>Meijer</surname><given-names>CJ</given-names></name></person-group><article-title>Epidemiologic classification of human papillomavirus types associated with cervical cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021641</pub-id><pub-id pub-id-type="pmid">12571259</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oany</surname><given-names>AR</given-names></name><name><surname>Emran</surname><given-names>AA</given-names></name><name><surname>Jyoti</surname><given-names>TP</given-names></name></person-group><article-title>Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach</article-title><source>Drug Des Devel Ther</source><year>2014</year><volume>21</volume><fpage>1139</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S67861</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandhi</surname><given-names>D</given-names></name><name><surname>Sonthalia</surname><given-names>S</given-names></name></person-group><article-title>Human papilloma virus vaccines: current scenario</article-title><source>Indian J Sex Transm Dis</source><year>2011</year><volume>32</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.4103/0253-7184.85409</pub-id><pub-id pub-id-type="pmid">22021967</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrosky</surname><given-names>E</given-names></name><name><surname>Bocchini</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name><surname>Hariri</surname><given-names>S</given-names></name><name><surname>Chesson</surname><given-names>H</given-names></name><name><surname>Curtis</surname><given-names>CR</given-names></name><name><surname>Saraiya</surname><given-names>M</given-names></name><name><surname>Unger</surname><given-names>ER</given-names></name><name><surname>Markowitz</surname><given-names>LE</given-names></name><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group><article-title>Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices</article-title><source>MMWR</source><year>2015</year><volume>64</volume><fpage>300</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">25811679</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>G</given-names></name><name><surname>Ferrante</surname><given-names>A</given-names></name><name><surname>Gorski</surname><given-names>J</given-names></name></person-group><article-title>Cross-reactivity of T cells and its role in the immune system</article-title><source>Crit Rev Immunol</source><year>2012</year><volume>32</volume><fpage>349</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v32.i4.50</pub-id><pub-id pub-id-type="pmid">23237510</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisani</surname><given-names>P</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name></person-group><article-title>Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden</article-title><source>Int J Cancer</source><year>1993</year><volume>55</volume><fpage>891</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910550604</pub-id><pub-id pub-id-type="pmid">8253525</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rammensee</surname><given-names>H</given-names></name><name><surname>Bachmann</surname><given-names>J</given-names></name><name><surname>Emmerich</surname><given-names>NP</given-names></name><name><surname>Bachor</surname><given-names>OA</given-names></name><name><surname>Stevanovi&#x00107;</surname><given-names>S</given-names></name></person-group><article-title>SYFPEITHI: database for MHC ligands and peptide motifs</article-title><source>Immunogenetics</source><year>1999</year><volume>50</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1007/s002510050595</pub-id><pub-id pub-id-type="pmid">10602881</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranjbar</surname><given-names>MM</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Ghorban</surname><given-names>K</given-names></name><name><surname>Nabian</surname><given-names>S</given-names></name><name><surname>Sazmand</surname><given-names>A</given-names></name><name><surname>Taheri</surname><given-names>M</given-names></name><name><surname>Esfandyari</surname><given-names>S</given-names></name><name><surname>Taheri</surname><given-names>M</given-names></name></person-group><article-title>Designing and modeling of complex DNA vaccine based on tropomyosin protein of Boophilus genus tick</article-title><source>Appl Biochem Biotechnol</source><year>2015</year><volume>175</volume><fpage>323</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1007/s12010-014-1245-z</pub-id><pub-id pub-id-type="pmid">25269597</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rautava</surname><given-names>J</given-names></name><name><surname>Syrj&#x000e4;nen</surname><given-names>S</given-names></name></person-group><article-title>Biology of human papillomavirus infections in head and neck carcinogenesis</article-title><source>Head Neck Pathol</source><year>2012</year><volume>6</volume><issue>1</issue><fpage>S3</fpage><lpage>S15</lpage><pub-id pub-id-type="doi">10.1007/s12105-012-0367-2</pub-id><pub-id pub-id-type="pmid">22782219</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reche</surname><given-names>PA</given-names></name><name><surname>Reinherz</surname><given-names>EL</given-names></name></person-group><article-title>Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms</article-title><source>J Mol Biol</source><year>2003</year><volume>331</volume><fpage>623</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(03)00750-2</pub-id><pub-id pub-id-type="pmid">12899833</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roomp</surname><given-names>K</given-names></name><name><surname>Antes</surname><given-names>I</given-names></name><name><surname>Lengauer</surname><given-names>T</given-names></name></person-group><article-title>Predicting MHC class I epitopes in large datasets</article-title><source>BMC Bioinform</source><year>2010</year><volume>17</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-11-90</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakib</surname><given-names>MS</given-names></name><name><surname>Islam</surname><given-names>MR</given-names></name><name><surname>Hasan</surname><given-names>AK</given-names></name><name><surname>Nabi</surname><given-names>AH</given-names></name></person-group><article-title>Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach</article-title><source>Adv Bioinform</source><year>2014</year><volume>2014</volume><fpage>402492</fpage><pub-id pub-id-type="doi">10.1155/2014/402492</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senapathy</surname><given-names>JG</given-names></name><name><surname>Umadevi</surname><given-names>P</given-names></name><name><surname>Kannika</surname><given-names>PS</given-names></name></person-group><article-title>The present scenario of cervical cancer control and HPV epidemiology in India: an outline</article-title><source>Asian Pac J Cancer Prev</source><year>2011</year><volume>12</volume><fpage>1107</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">21875253</pub-id></element-citation></ref><ref id="CR48"><mixed-citation publication-type="other">Shannon CE (1948) The mathematical theory of communication. Bell Syst Tech J 27:379&#x02013;423 and 623&#x02013;656</mixed-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Arya</surname><given-names>DK</given-names></name><name><surname>Sagar</surname><given-names>V</given-names></name><name><surname>Bergmann</surname><given-names>R</given-names></name><name><surname>Chhatwal</surname><given-names>GS</given-names></name><name><surname>Johri</surname><given-names>AK</given-names></name></person-group><article-title>Identification of potential universal vaccine candidates against group A Streptococcus by using high throughput in silico and proteomics approach</article-title><source>J Proteome Res</source><year>2013</year><volume>12</volume><fpage>336</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1021/pr3005265</pub-id><pub-id pub-id-type="pmid">23181284</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>LJ</given-names></name><name><surname>Wiley</surname><given-names>DC</given-names></name></person-group><article-title>Antigenic peptide binding by class I and class II histocompatibility proteins</article-title><source>Structure</source><year>1994</year><volume>2</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/S0969-2126(00)00026-5</pub-id><pub-id pub-id-type="pmid">8087551</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobel</surname><given-names>I</given-names></name><name><surname>Berchtold</surname><given-names>S</given-names></name><name><surname>G&#x000f6;tze</surname><given-names>A</given-names></name><name><surname>Schulze</surname><given-names>U</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name><name><surname>Steinkasserer</surname><given-names>A</given-names></name></person-group><article-title>Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes</article-title><source>Gene Ther</source><year>2000</year><volume>7</volume><fpage>2028</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301326</pub-id><pub-id pub-id-type="pmid">11175315</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumalee</surname><given-names>S</given-names></name><name><surname>Supaporn</surname><given-names>S</given-names></name><name><surname>Jongkolnee</surname><given-names>S</given-names></name><name><surname>Surapan</surname><given-names>K</given-names></name><name><surname>Kobkul</surname><given-names>T</given-names></name><name><surname>Anusorn</surname><given-names>B</given-names></name><name><surname>Chaisuksunt</surname><given-names>V</given-names></name><name><surname>Lekawanvijit</surname><given-names>S</given-names></name><name><surname>Srisomboon</surname><given-names>J</given-names></name><name><surname>Thorner</surname><given-names>PS</given-names></name></person-group><article-title>HPV genotyping in cervical cancer in Northern Thailand Adapting the linear array HPV assay for use on paraffin-embedded tissue</article-title><source>Gynecol Oncol</source><year>2008</year><volume>108</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2007.11.016</pub-id><pub-id pub-id-type="pmid">18199473</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Supindham</surname><given-names>T</given-names></name><name><surname>Chariyalertsak</surname><given-names>S</given-names></name><name><surname>Utaipat</surname><given-names>U</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Ruanpeng</surname><given-names>D</given-names></name><name><surname>Chotirosniramit</surname><given-names>N</given-names></name><name><surname>Kosashunhanan</surname><given-names>N</given-names></name><name><surname>Sugandhavesa</surname><given-names>P</given-names></name><name><surname>Saokhieo</surname><given-names>P</given-names></name><name><surname>Songsupa</surname><given-names>R</given-names></name><name><surname>Siriaunkgul</surname><given-names>S</given-names></name><name><surname>Wongthanee</surname><given-names>A</given-names></name></person-group><article-title>A high prevalence and genotype diversity of anal HPV infection among MSM in Northern Thailand</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0124499</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0124499</pub-id><pub-id pub-id-type="pmid">25932915</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Poveda</surname><given-names>K</given-names></name><name><surname>Bahena-Rom&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Madrid-Gonz&#x000e1;lez</surname><given-names>C</given-names></name><name><surname>Burguete-Garc&#x000ed;a</surname><given-names>AI</given-names></name><name><surname>Berm&#x000fa;dez-Morales</surname><given-names>VH</given-names></name><name><surname>Peralta-Zaragoza</surname><given-names>O</given-names></name><name><surname>Madrid-Marina</surname><given-names>V</given-names></name></person-group><article-title>Role of IL-10 and TGF-&#x003b2;1 in local immunosuppression in HPV-associated cervical neoplasia</article-title><source>World J Clin Oncol</source><year>2014</year><volume>10</volume><fpage>753</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.5306/wjco.v5.i4.753</pub-id><pub-id pub-id-type="pmid">25302175</pub-id></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdespino</surname><given-names>V</given-names></name><name><surname>Gorodezky</surname><given-names>C</given-names></name><name><surname>Ortiz</surname><given-names>V</given-names></name><name><surname>Kaufmann</surname><given-names>AM</given-names></name><name><surname>Roman-Basaure</surname><given-names>E</given-names></name><name><surname>Vazquez</surname><given-names>A</given-names></name><name><surname>Berumen</surname><given-names>J</given-names></name></person-group><article-title>HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients</article-title><source>Gynecol Oncol</source><year>2005</year><volume>96</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2004.08.052</pub-id><pub-id pub-id-type="pmid">15589586</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wain</surname><given-names>G</given-names></name></person-group><article-title>The human papillomavirus (HPV) vaccine, HPV related diseases and cervical cancer in the post-reproductive years</article-title><source>Maturitas</source><year>2010</year><volume>65</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2009.12.002</pub-id><pub-id pub-id-type="pmid">20036786</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Bennink</surname><given-names>JR</given-names></name></person-group><article-title>Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses</article-title><source>Annu Rev Immunol</source><year>1999</year><volume>17</volume><fpage>51</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.17.1.51</pub-id><pub-id pub-id-type="pmid">10358753</pub-id></element-citation></ref></ref-list></back></article>